🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524773-16-00
Authorised Phase I

A study in healthy people to compare how 2 different formulations of vicadrostat / empagliflozin tablets are taken up in the body

2025-524773-16-00 · tracked via the Priya Life Science EU tracker
Sponsor
Boehringer Ingelheim International GmbH
Sponsor type
Pharmaceutical company
Therapeutic area
Not possible to specify
Decision date
06/08/2026
Enrollment target
36
Sites
Germany

Condition studied

Healthy

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524773-16-00 on CTIS ↗ ← All trials in the EU